ClinicalTrials.gg
TerminatedNCT00904397Updated Feb 15, 2010

Lidocaine Patch 5% Versus Celecoxib 200 mg in Chronic Axial Low Back Pain

A Phase 4 interventional study of Lidoderm® and Celecoxib in Chronic Low Back Pain, sponsored by Endo Pharmaceuticals. Terminated at 21 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2010-02-15.

Sponsored by Endo Pharmaceuticals (part of Keenova Therapeutics plc) · Phase 4, Interventional, and Treatment

Why this study was terminated
Rofecoxib was withdrawn from the market due to safety concerns.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
98
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 711 studies in Low Back Pain with a site in United States — 99 open to participants now, 125 under way, 3 of them phase 3. Low Back Pain · United States.

Enrollment
279th of 623
98 · median 79
Started
2004
with 14 others
Phase 4
50 of 711
4 open now
Registered
121st of 711
by date

Among the 711 studies in Low Back Pain with a site in United States, this one is the 279th largest by enrollment of the 623 interventional ones that give a count, is one of 15 that started in 2004, is one of 50 in phase 4, and was the 121st registered.

Low Back Pain

2,926 studies on the registry are indexed under Low Back Pain; 579 are open to participants now.

Browse Low Back Pain studies →

Open to participants now

99 of the 711 studies in Low Back Pain with a site in United States are open now. Recruiting first, the newest first:

94 more — sign in →

All 99 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 332 Low Back Pain studies recruiting now, 92 (28%) set no upper age limit and 210 (63%) stop at 75 or younger; 8 take children under 18; 46 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 711 studies in Low Back Pain with a site in United States, or all of them as a file.
02

Study summary

Patients who had axial lower back pain (LBP) with or without radiation present for at least 3 months and had daily moderate to severe LBP as the primary source of pain participated in a Phase IV clinical trial to assess the efficacy of lidocaine patch 5% compared to celecoxib 200 mg in treating chronic axial LBP with and without radiation.

03

Conditions studied

  • Chronic Low Back Pain

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Had axial LBP with or without radiation present for at least 3 months as defined below:

    • Chronic axial LBP without radiation: pain isolated to the axial low back without radiation into the buttock or below
    • Chronic axial LBP with radiation: pain that radiated to the buttock or below. This patient group could include patients with radicular/neuropathic and non-radicular components with leg pain component \<50%
  2. Had daily moderate to severe LBP as the primary source of pain
  3. Had a normal neurological examination, including:

    • Motor strength
    • Sensory exam in lower extremities
    • Deep tendon reflexes
  4. Had a normal 12-lead (ECG) without any abnormalities in heart rate, rhythm, or conduction
  5. Had discontinued use of all analgesic medications (including over-the-counter [OTC] analgesics), glucosamine, and chondroitin prior to randomization (patients were allowed limited use of analgesic medications for indications other than non-study pain
  6. At the baseline visit, patients were randomized to active treatment if they had an average daily pain intensity score of 5 or greater (on a 0 to 10 scale) for at least 3 days out of the 5 consecutive days immediately prior to the baseline visit; 0 was defined as "no pain" and 10 was defined as "pain as bad as ever imagined" as measured by Question 5 of the Brief Pain Inventory (BPI) and recorded in a diary

Exclusion criteria

Exclusion Criteria:

  1. Had spinal stenosis with >50% leg pain component
  2. Had any other chronic pain condition that, in the opinion of the investigator, would interfere with patient assessment of LBP relief
  3. Had a history of one or more back surgeries within 1 year of study entry
  4. Had a moderate or greater hepatic impairment
  5. Had a severe renal insufficiency ( of \<30 mL/min)
  6. Had experienced asthma, urticaria, or allergic-type reactions after taking aspirin or other nonsteroidal anti-inflammatory drugs (NSAIDs)
  7. Had a prior history of peptic ulcer disease and/or gastrointestinal (GI) bleeding
  8. Were taking analgesic medications that could not be discontinued during the study. Patients taking these medications prior to the study were required to discontinue use for the duration of the study. Patients using opioid analgesics at study entry were required to taper off these medications.
  9. Were taking long-acting opioids or opioids that could not be discontinued over the first 5 days of the
  10. Were receiving fluconazole or lithium (secondary to drug-drug-interaction risks with celecoxib)
  11. Had received an epidural /local anesthetic injection within 4 weeks prior to study entry
  12. Had received trigger point injections within 2 weeks prior to study entry
  13. Had received Botulinum Toxin (Botox) injections for LBP within 6 months prior to study entry
  14. Were using a lidocaine-containing product that cannot be discontinued during the study
  15. Were using any topical medication applied to the low back region
  16. Had previously failed treatment with Lidoderm analgesic patch for LBP
  17. Had previously failed treatment with celecoxib or with any two COX-2 specific inhibitors other than celecoxib
  18. Were taking class I anti-arrhythmic (e.g. mexiletine, tocainide)
  19. Had a history of alcohol or substance abuse within the last 3 years
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Washout period

A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
98 participants (actual)

Study arms

  • Experimental
    Lidoderm

    Lidocaine patch 5% (Lidoderm®, Endo Pharmaceuticals Inc.), 2 patches applied once daily (q24h) directly to the most painful area of the low back

    Drug: Lidoderm®

  • Active comparator
    Celecoxib

    Celecoxib (Celebrex®, G.D. Searle \& Co., Chicago, IL), one 200 mg oral capsule QD

    Drug: Celecoxib

Interventions

  • Patients participated in a 14-day washout period followed by a 12-week active treatment period. Eligible patients were randomized equally to one of two groups: lidocaine patch 5% or celecoxib 200 mg.

    Also known as: Lidocaine patch 5%

  • Patients participated in a 14-day washout period followed by a 12-week active treatment period. Eligible patients were randomized equally to one of two groups: lidocaine patch 5% or celecoxib 200 mg.

06

What researchers measure

Primary outcomes

  1. Mean change from baseline to Week 12 in BPI average pain intensity score (Question 5).

    Time frame: Visit - V2 (Day 0), V3 (Day 14), V4 (Day 28), V5 (Day 42), V6 (Day 56), V7 (Day 84)

Secondary outcomes

  1. Mean change from baseline to Weeks 2, 4, 6, 8, and 12 in daily pain intensity score as measured by Questions 3, 4, 5, and 6 of the BPI

    Time frame: Visit - V2 (Day 0), V3 (Day 14), V4 (Day 28), V5 (Day 42), V6 (Day 56), V7 (Day 84)

  2. Mean change from baseline to Weeks 2, 4, 6, 8, and 12 in BPI pain relief score (Question 8).

    Time frame: Visit - V2 (Day 0), V3 (Day 14), V4 (Day 28), V5 (Day 42), V6 (Day 56), V7 (Day 84)

  3. Mean change from baseline to Weeks 2, 4, 6, 8, and 12 in PQAS composite scores

    Time frame: Visit - V2 (Day 0), V3 (Day 14), V4 (Day 28), V5 (Day 42), V6 (Day 56), V7 (Day 84)

  4. Mean change from baseline to Weeks 2, 4, 6, 8, and 12 in Oswestry Disability Index composite scores

    Time frame: Visit - V2 (Day 0), V3 (Day 14), V4 (Day 28), V5 (Day 42), V6 (Day 56), V7 (Day 84)

  5. Investigator's Global Impression of Change in LBP at Week 12 (or premature discontinuation)

    Time frame: Visit - V2 (Day 0), V3 (Day 14), V4 (Day 28), V5 (Day 42), V6 (Day 56), V7 (Day 84)

  6. Patient's Global Impression of Change in LBP at Week 12 (or premature discontinuation)

    Time frame: Visit - V2 (Day 0), V3 (Day 14), V4 (Day 28), V5 (Day 42), V6 (Day 56), V7 (Day 84)

  7. Investigator's Global Assessment of Treatment Satisfaction at Week 12 (or premature discontinuation)

    Time frame: Visit - V2 (Day 0), V3 (Day 14), V4 (Day 28), V5 (Day 42), V6 (Day 56), V7 (Day 84)

  8. Patient's Global Assessment of Treatment Satisfaction at Week 12 (or premature discontinuation)

    Time frame: Visit - V2 (Day 0), V3 (Day 14), V4 (Day 28), V5 (Day 42), V6 (Day 56), V7 (Day 84)

  9. Safety assessments included AEs (including discontinuation due to AEs).

    Time frame: Visit - V2 (Day 0), V3 (Day 14), V4 (Day 28), V5 (Day 42), V6 (Day 56), V7 (Day 84)

  10. Safety assessments included dermal assessment (lidocaine group only), skin sensory testing (lidocaine group only), clinical laboratory test results (including urinalysis, vital signs measurements, physical and neurological examinations, and body weight.

    Time frame: Visit - V2 (Day 0), V3 (Day 14), V4 (Day 28), V5 (Day 42), V6 (Day 56), V7 (Day 84)

  11. Safety assessments included plasma lidocaine concentrations (lidocaine group only).

    Time frame: Visit - V2 (Day 0), V3 (Day 14), V4 (Day 28), V5 (Day 42), V6 (Day 56), V7 (Day 84)

07

Study locations

21 sites
  • Northport, Alabama, United States
  • Phoenix, Arizona, United States
  • Beverly Hills, California, United States
  • Encinitas, California, United States
  • San Diego, California, United States
  • Spring Valley, California, United States
  • Longwood, Florida, United States
  • North Miami Beach, Florida, United States
  • Plantation, Florida, United States
  • Chicago, Illinois, United States
  • Shreveport, Louisiana, United States
  • Boston, Massachusetts, United States
  • Berlin, New Jersey, United States
  • Beth Page, New York, United States
  • Tonawanda, New York, United States
  • Charlotte, North Carolina, United States
  • Dayton, Ohio, United States
  • Allentown, Pennsylvania, United States
  • Sellersville, Pennsylvania, United States
  • Greer, South Carolina, United States
  • Spokane, Washington, United States
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jul 2004 and a primary completion of Nov 2004. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
May 15, 2009
First posted
May 19, 2009
Start
Jul 2004
Primary completionActual
Nov 2004
Last update
Feb 15, 2010
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 15, 2010, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT00904397
First posted
May 19, 2009
Start date
Jul 2004
Primary completion
Nov 2004
Last update
Feb 15, 2010

Study contacts

Sr. Director
study director · Endo Pharmaceuticals
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Feb 2010. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Lidoderm

Start the discussion